
by Ken Wahl, VP Business Development, Data Insights, Guidepoint Nevro Corp. (NYSE: NVRO) is a key player in the spinal cord stimulation (SCS) market. Since FDA approval of the Senza system in 2015, Nevro has taken ~15% market share from well-established market leaders Abbott/St. Jude, Medtronic and Boston Scientific. The U.S. SCS market was an […]
Read More